Current Approaches Against Alzheimer's Disease in Clinical Trials

• Autor(a) principal: Kuca,Kamil
• Data de Publicação: 2016
• Outros Autores: Soukup,Ondrej, Maresova,Petra, Korabecny,Jan, Nepovimova,Eugenie, Klimova,Blanka, Honegr,Jan, Ramalho,Teodorico C., França,Tanos C. C.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Journal of the Brazilian Chemical Society (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532016000400641
• topic: Alzheimer's disease; treatment; tacrine; rivastigmine; galantamine; donepezil; huperzine A; arecoline; AC-42; encenicline; ABT-126; rosiglitazone; pioglitazone; atorvastatin; thalidomide; minocycline; semagacestat; epigallocatechin gallate; etazolate; tramiprosate; valproic acid; tideglusib; methylene blue; immunotherapy

Alzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a drug for AD is enormous. However, despite the long-term and worldwide effort for a more effective therapy, the only available treatment is a symptomatic use of acetylcholinesterase inhibitors (AChEIs) and memantine. New therapeutic approaches as well as those based on cholinergic or amyloid theory have not brought the desired benefits yet. Thus, the question is whether an effective drug for this progressive disease will ever be developed or whether people will have to rely only on prevention and minimize risk factors of AD.